RxDoctor Payments Data

Noelle Maude, NP

Family · Rochester Hills, MINPI 1275062184

Payments from drug & device makers

$5,330in general payments, 2019–2025

Across 155 payments — averaging $34.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • AbbVie$1K
  • Johnson & Johnson$348
  • Takeda Pharmaceuticals U.S.A., Inc.$282
  • Sanofi$179
  • Nestle Healthcare Nutrition Inc.$175
  • plus $1K from 21 others

What the payments were for

  • Consulting fees$70013%
  • Travel & lodging$2364%
  • Food & beverage$4,39482%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,330 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$350,523
Medicare patients
368
Services billed
20,445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin22$68,243
CreonLipase/Protease/Amylase27$67,863
ZenpepLipase/Protease/Amylase16$46,057
LinzessLinaclotide32$34,327
Mesalamine25$11,915
Balsalazide Disodium15$5,315
Pantoprazole Sodium203$4,498
Dicyclomine Hcl125$3,320
Omeprazole162$3,176
Ursodiol11$3,065
Budesonide EcBudesonide14$2,947
Famotidine176$2,813
Colestipol Hcl28$2,103
PentasaMesalamine11$1,906
Sucralfate40$1,527

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,147$102,19159 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,978$68,24322 claims
Aimmune Therapeutics, Inc.Zenpep$47$46,05716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.

Other family in Rochester Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →